PRiming IMmunity At the
beginning of Life



PRiming IMmunity At the beginning of Life


Project 5


Impact of immaturity and the microbiome on the vaccine response in infants

Project Summary

Aim: To characterize the immune responses to routine vaccination (Diphtheria, Polio, Pertussis, Tetanus, Haemophilus influenzae b, Hepatitis B) in very preterm neonates of the PRIMAL Clinical Study, which are randomized to the administration of probiotics or placebo.

Design: We will characterize

  • the acute non-specific inflammatory response 1-3 days after vaccination
  • the primary adaptive immune response 5-7 days after vaccination
  • And the long-term adaptive immune response (12 months) after vaccination in participants of the PRIMAL study cohort.

Expected outcome: We expect probiotics to better understand if and how the gut immaturity and the gut microbiota influence the immune response to routine vaccination.


Michael Zemlin

Prof. Dr. med. Michael Zemlin

Direktor der Klinik für Allgemeine Pädiatrie und Neonatologie
UKS – Universitätsklinikum des Saarlandes
Kirrberger Straße
D-66421 Homburg (Saarland)

E-Mail: michael.zemlin@uks.eu
Telefon: +49 (0) 6841 162 8301